Why Antares Pharma Inc. Shares Temporarily Popped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Antares Pharma , a specialty biopharmaceutical company focused on developing self-administered and topical-gel medications, advanced as much as 14% after announcing the Food and Drug Administration's approval of its Otrexup injection for the treatment of adults with rheumatoid arthritis, adults with psoriasis, and children with polyarticular idiopathic arthritis. Shares have since given back most of their gains are now up just 4% as of this writing.

So what: Otrexup itself is a once-weekly subcutaneous injection self-administered by the patient. It will act as a second-line therapy for rheumatoid arthritis patients who are intolerant to oral methotrexate or who have demonstrated poor response. In addition, in human study trials Antares found that injectable methotrexate demonstrated increased bioavailability relative to oral methotrexate, giving the company hope that it will become a go-to medication for second-line rheumatoid arthritis disease control. Antares plans to launch Otrexup in early 2014.


Now what: There's absolutely no way to spin this other than the fact that it's great news for Antares and its shareholders. According to the company's own estimates, Otrexup could have peak sales potential ranging from $100 million to $200 million. At the midpoint of that guidance, and including its other approved products, Antares is currently valued at close to three times peak sales estimates. I'm not willing to go out on a limb and say Antares is richly valued yet -- but it's also not much of a bargain in my eyes, either. I believe we need to take a step back and see how well Antares executes the launch of Otrexup before we can have a really good bead on where it heads next.

Two biotechs that could completely revolutionize the sector
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

The article Why Antares Pharma Inc. Shares Temporarily Popped originally appeared on Fool.com.

Fool contributor  Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle  @TMFUltraLong . Try any of our Foolish newsletter services free for 30 days . We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights  makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investor’s Toolbox

Improve your investing savvy with the right financial toolset.

View Course »

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Add a Comment

*0 / 3000 Character Maximum